CRYPTO 5%

Research-grade peptides. Shipped same day in Bangkok.

07 / Ipamorelin

Ipamorelin

Available as ORIN

Molecular profile
Sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2
Formula C38H49N9O5
Class Selective growth hormone secretagogue

A selective growth hormone secretagogue (ghrelin / GHS-receptor agonist), a synthetic pentapeptide containing two non-standard residues, 2-aminoisobutyric acid and D-2-naphthylalanine, with a C-terminal amide. Studied for growth hormone release via a GHRP-like receptor without significant change in ACTH, cortisol, or prolactin.

Selectivity as a secretagogue

The 1998 founding study reported that ipamorelin released growth hormone from primary rat pituitary cells with potency and efficacy comparable to GHRP-6, acting via a GHRP-like receptor, and that unlike some earlier secretagogues it did so without raising ACTH or cortisol.

Skeletal research in rats

A 1999 study injected ipamorelin at 18, 90, and 450 micrograms per day into adult female rats for 15 days and reported a dose-dependent increase in longitudinal bone growth rate at the proximal tibia (42 to 52 micrometres per day), with no change in total IGF-I.

Gastrointestinal motility

A 2012 study in a rodent model of postoperative ileus reported that ipamorelin, a ghrelin mimetic, accelerated gastric emptying through a GHS-receptor-mediated cholinergic mechanism.

Peer-reviewed references

  • Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi.org/10.1530/eje.0.1390552
  • Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. doi.org/10.1054/ghir.1999.9998
  • Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. J Exp Pharmacol. 2012;4:149-155. doi.org/10.2147/JEP.S35396

Library

Research and Whitepapers

Ipamorelin: The First Selective Growth Hormone Secretagogue

Ipamorelin is a five-residue peptide developed at Novo Nordisk in the 1990s. Its defining property in the literature is selectivity: it releases growth hormone in study models without the cortisol and prolactin changes seen with earlier secretagogues.

For research purposes only. Not for human or veterinary consumption. Not for use in diagnostic, therapeutic, or clinical procedures.